Table 1 Baseline demographics and clinical characteristics

From: Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study

 

Patients (N = 46)

Age (yrs)

 Median (range)

67 (30–80)

 < 65

18 (39.1)

 ≥ 65

28 (60.9)

Sex

 Male

20 (43.4)

 Female

26 (56.5)

Primary site

 Intrahepatic

28 (60.9)

 Extrahepatic

11 (23.9)

 Gallbladder

5 (10.9)

 Ampulla vater

2 (4.3)

Disease status

 Locally advanced

6 (13)

 Distant Metastasis

40 (87)

Chronic hepatitis

 HBV

12 (26)

 HCV

2 (4)

Treatment response

 Responders

21 (45.6)

 Non-responders

25 (54.3)

PD-L1 expression

 CPS ≥ 1

19 (41.3)

 CPS ≥ 10

13 (28.3)

 Not assessable

1 (2.2)

TMB

 TMB-H ( ≥ 7.1 mut/Mb)

7 (15.2)

 TMB-L ( < 7.1 mut/Mb)

25 (54.3)

 Not assessable

14 (30.4)

  1. PD-L1 programmed death-ligand 1, CPS combined positive score, TMB tumo mutation burden, TMB-H tumor mutation burden high, TMB-L tumor mutation burden low.
Back to article page